Global polyclonal antibodies market expected to reach USD 2.2 billion by 2033, with growth opportunities in Asia-Pacific region.

From GlobeNewswire: 2024-05-31 02:00:00

The Global Polyclonal Antibodies Market Size is expected to reach USD 2.2 Billion by 2033, with a CAGR of 5.40% during the projected period. Polyclonal antibodies are a mixture of antibodies from different animal B-cell clones, offering advantages in binding epitopes on cancer cells. Factors like high costs and cross-reactivity may limit market growth. The secondary antibody segment dominates the market, with rabbits being the main source. Pharmaceutical and biotechnology companies are the largest end-users. North America leads the market, while the Asia-Pacific region is expected to grow fastest. Key players in the market include Abcam, Thermo Fisher Scientific, and Merck. Recent developments include positive results from SAB Biotherapeutics in producing fully-human anti-idiotype polyclonal antibodies. Market segmentation includes product type, source, end-user, and region. Other related reports cover topics such as Electrical Stimulators, AI in healthcare, Chronic Wound Care, and Human Microchipping. Spherical Insights & Consulting offers comprehensive market research and consulting services to support decision-making and business strategies.



Read more at GlobeNewswire: Global Polyclonal Antibodies Market Size To Exceed USD 2.2